**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

In a report, two women (a 64-year-old and a 58-year-old woman) were described, who developed Coronavirus disease 2019 (COVID-19) infection during treatment with hydroxychloroquine for mixed connectivitis and rheumatoid arthritis, respectively \[*routes and duration of treatments to reactions onset not stated*\].

The 64-year-old woman with a history of mixed connectivitis, had been receiving long-term therapy with hydroxychloroquine 400mg once a day. She was admitted due to nausea, fever, major headaches and myalgias from 10 days. Her family members had also been admitted previously due to confirmed COVID-19. She had discontinued hydroxychloroquine one day prior to admission due to nausea. On admission, her physical examination showed RR of 25 breaths/minute, body temperature of 38.5°C and oxygen saturation 85% in ambient air. Laboratory investigation revealed elevated CRP levels. A nasopharyngeal swab was collected and COVID-19 reverse transcription (RT)-PCR performed on the same day revealed positive result, which confirmed COVID-19 infection. Thirty six hours after the last dose of hydroxychloroquine, her plasma drug concentration was 222 ng/mL. Based on these findings and clinical presentation, it was concluded that the treatment with hydroxychloroquine might have contributed in the development of COVID-19 infection. On the next day, her oxygen saturation improved, and she was discharged based on clinical severity criteria.

The 58-year-old woman with history of rheumatoid arthritis, had been receiving long-term therapy with hydroxychloroquine 400mg once a day along with prednisone for long-time with a good treatment adherence. She was hospitalised to the emergency room due to asthenia and fever for 1 week. Two days prior to admission, she was prescribed with azithromycin by the family doctor. On admission, her oxygen saturation was 91% requiring oxygen therapy and body temperature was 39°C. Laboratory investigation revealed elevated CRP levels. A chest CT scan revealed moderate stage ground-glass opacities. A nasopharyngeal swab was collected and COVID-19 reverse transcription (RT)-PCR was performed which revealed positive result and COVID-19 infection had confirmed. During admission, her prednisone was discontinued; however, her treatment with hydroxychloroquine was continued. On admission day 1, her plasma hydroxychloroquine level was 407 ng/mL. Based on these findings and clinical presentation, it was concluded that the treatment with hydroxychloroquine might have contributed in the development of COVID-19 infection. Later, a progressive clinical improvement was noted .
